[Recent findings and advances in treatment of myeloproliferative neoplasms].

Abstract excerpt

Many novel agents have been developed for BCR::ABL1-negaive myeloproliferative neoplasms (MPN), namely, polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). Some of these agents not only achieve hematologic complete response, reduce spleen size, and alleviate constitutional symptoms, but also induce molecular response, which means that they reduce the allele burden of driver...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Molecular Targeted Therapy
• Share to Mutation
• Share to Myeloproliferative Disorders